WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that four abstracts have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, taking place November 7–11 in Washington, D.C. Three presentations will feature data on imdusiran (AB-729), the company’s RNAi therapeutic for chronic hepatitis B virus (cHBV), while one presentation on AB-101, its PD-L1 inhibitor, has been designated as a Poster of Distinction.
The accepted imdusiran studies highlight the therapy’s safety, immune activation, and potential to enhance interferon responsiveness in cHBV patients. Data from integrated Phase 1 and 2 analyses show that imdusiran is well tolerated when administered every eight weeks for up to 48 weeks, with consistent safety across 60 mg and 90 mg dosing levels.
Another study, IM-PROVE I, explores how imdusiran may improve responsiveness to pegylated interferon alfa-2a, particularly in patients with HBV genotypes B and C, contrasting with historical response patterns. A third imdusiran presentation details elevated immune biomarkers in patients achieving hepatitis B surface antigen (HBsAg) loss, suggesting a correlation between immune activation and functional cure potential.
The Poster of Distinction presentation will focus on AB-101, Arbutus’s small-molecule PD-L1 inhibitor designed to achieve targeted checkpoint blockade with fewer systemic side effects than antibody therapies. Interim data show that oral doses up to 30 mg daily for 28 days were generally well tolerated in NA-suppressed cHBV patients, with dose-dependent increases in receptor occupancy reaching 83% at the 30 mg level. The ongoing Phase 1a/1b trial continues to evaluate safety, pharmacokinetics, and biomarker outcomes.
Arbutus’s imdusiran program aims to reduce viral proteins, including HBsAg, enabling immune reactivation against HBV. The company has reported eight patients achieving a functional cure following combination therapy with imdusiran and nucleos(t)ide analogs paired with interferon or nivolumab-based regimens.
The accepted abstracts will be available on the AASLD website and published in the October 2025 supplement of Hepatology. Poster presentations will go live on November 7 at 8:00 a.m. ET and can also be accessed on Arbutus Biopharma’s website at www.arbutusbio.com/publications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.